An ABC-type multidrug transporter of Lactococcus lactis possesses an exceptionally broad substrate specificity

doi:10.1054/drup.2000.0173

Drug Resistance Updates

Volume 3, Issue 6, December 2000, Pages 330-334

https://doi.org/10.1054/drup.2000.0173 Get rights and content

Abstract

LmrA is a 590-amino acid membrane protein which confers multidrug resistance on Lactococcus lactis cells by extruding amphiphilic compounds from the inner leaflet of the cytoplasmic membrane at the expense of ATP hydrolysis. Its structural and functional characteristics place it in the P-glycoprotein cluster of the ATP-binding cassette transporter superfamily, making it the first prokaryotic multidrug transporter of this cluster. The number of compounds recognized and transported by LmrA is remarkably vast and includes many lipophilic cations as well as a record of eight classes of clinically relevant broad-spectrum antibiotics. Homologs of LmrA have been found in pathogenic bacteria, suggesting that these putative efflux pumps may play a crucial role in antibiotic resistance of human pathogens. Recent evidence indicates that LmrA is functional as a homodimer, consistent with the overall structure of P-glycoprotein, and mediates drug transport by an alternating two-site transport mechanism.

References (33)

H. Bolhuis et al.
The Lactococcal lmrP gene encodes a proton motive force-dependent drug transporter
J Biol Chem
(1995)
M.F. Rosenberg et al.
Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis
J Biol Chem
(1997)
T.W. Loo et al.
Determining the structure and mechanism of the human multidrug resistance P-glycoprotein using cysteine scanning mutagenesis and thiol-modification techniques
Biochim Biophys Acta
(1999)
L. Homolya et al.
Fluorescent cellular indicators are extruded by the multidrug resistance protein
J Biol Chem
(1993)
A.H. Schinkel et al.
Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
Cell
(1994)
P. Borst et al.
ABC transporters in lipid transport
Biochim Biophys Acta
(2000)
Y. Raviv et al.
Photosensitized labeling of a functional multidrug transporter in living drug resistant tumor cells
J Biol Chem
(1990)
C.F. Higgins et al.
Is the multidrug transporter a flippase?
Trends Biochem Sci
(1992)
L.M. Greenberger
Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12
J Biol Chem
(1993)
A.E. Senior et al.
The catalytic cycle of P-glycoprotein
FEBS Lett
(1995)

N. Sonveaux et al.

Secondary and tertiary structure changes of reconstituted P-glycoprotein

J Biol Chem

(1996)

N. Sonveaux et al.

Ligand-mediated tertiary structure changes of reconstituted P-glycoprotein

J Biol Chem

(1999)

C. Vigano et al.

Secondary and tertiary changes of reconstituted LmrA induced by nucleotide binding or hydrolysis

J Biol Chem

(2000)

H. Nikaido

Prevention of drug access to bacterial targets: permeability barriers and active efflux

Science

(1994)

M.M. Gottesman

How cancer cells evade chemotherapy

Cancer Res

(1993)

M. Putman et al.

Molecular properties of bacterial multidrug transporters

Microbiol Mol Biol Rev

(2000)

Cited by (30)

Efflux pump as alternate mechanism for drug resistance in Mycobacterium tuberculosis
2019, Indian Journal of Tuberculosis
Citation Excerpt :
The mechanisms for the expression and regulation of these efflux pumps are not yet fully understood. Moreover, their role in drug resistance needs to be understood.15 In Mycobacterium smegmatis as well as in other mycobacteria, the cell wall, rich in mycolic acids, functions as an efficient barrier preventing the access of several molecules including antibiotics.
Tuberculosis (TB) remains an important global public health issue with an approximate prevalence of 10 million people with TB worldwide in 2015. Since antibiotic treatment is one of the foremost tools for TB control, knowledge of Mycobacterium tuberculosis (MTB) drug resistance is an important component for disease control. Although gene mutations in specific loci of the MTB genomes are reported as the primary basis for drug resistance, additional mechanisms conferring resistance to MTB are thought to exist. Efflux is a ubiquitous mechanism responsible for innate and acquired drug resistance in prokaryotic and eukaryotic cells. MTB presents a large number of putative drug efflux pumps compared to its genome size. Bioinformatics-based evidence has shown an association between drug efflux and innate or acquired resistance in MTB. This review describes the recent understanding of drug efflux in MTB.
Single nucleotide polymorphisms in efflux pumps genes in extensively drug resistant Mycobacterium tuberculosis isolates from Pakistan
2017, Tuberculosis
Citation Excerpt :
The mechanisms for the expression and regulation of these efflux pumps are not yet fully understood. Moreover, their role in drug resistance needs to be understood [9]. Although efflux mechanisms have been studied in several mycobacteria [10–12] mostly, M. smegmatis has been used to study heterologous putative efflux pump genes [13–16].
It is challenging to understand mechanisms of drug resistance in Mycobacterium tuberculosis (MTB) due to the large variability in resistance associated genes. Efflux pump genes contribute to drug resistance and thus add to this complexity. Efflux pump gene protein superfamilies have been characterized by genome analysis of drug resistant strains and through in vitro transcriptional studies. However, there is limited information regarding efflux pump genes in extensively drug resistant (XDR) tuberculosis (TB) isolates.
Whole genome sequencing (WGS) based analysis of 37 extensively drug resistant (XDR) and five drug sensitive (DS) MTB clinical isolates was performed. Single nucleotide polymorphisms (SNPs) in efflux pump genes Rv0194, Rv1217, Rv1218, drrA, drrB, Rv1258, Rv1634, Rv2688, Rv1273, Rv1819, Rv1458, Rv1877 and Rv1250 were determined in the clinical isolates as compared with the H37Rv reference strain. Allele frequencies of SNPs identified in XDR strains were compared with DS strains. Gene expression of Rv0194, Rv2688, Rv1634, drrA and drrB was determined in XDR -TB isolates (n = 9), DS-TB strains (n = 4) and H37Rv.
We identified SNPs in XDR-TB isolates which were either unique or present at very low frequencies in DS strains; Rv0194 G170V; Rv1217 L151R; Rv1258 P369T and G391R; Rv1273 S118G and I175T; Rv1877 I534T; Rv1250 V318X/A and S333A, and Rv2688 P156T. The expression of Rv2688 and drrB was found to be raised in XDR-TB as compared with DS-TB strains.
We identified unique SNPs in efflux pump genes which may be associated with increased drug resistance in the isolates. Increased levels of Rv2688 and drrB efflux pump gene expression observed in XDR strains even in the absence of antibiotics suggests that these clinical isolates may be more refractory to treatment. Further studies are required to directly associate these mutations with increased resistance in MTB.
ATP hydrolysis and pristinamycin IIA inhibition of the Staphylococcus aureus Vga(A), a dual ABC protein involved in streptogramin A resistance
2008, Journal of Biological Chemistry
In Gram-positive bacteria, a large subfamily of dual ATP-binding cassette proteins confers acquired or intrinsic resistance to macrolide, lincosamide, and streptogramin antibiotics by a far from well understood mechanism. Here, we report the first biochemical characterization of one such protein, Vga(A), which is involved in streptogramin A (SgA) resistance among staphylococci. Vga(A) is composed of two nucleotide-binding domains (NBDs), separated by a charged linker, with a C-terminal extension and without identified transmembrane domains. Highly purified Vga(A) displays a strong ATPase activity (K_m = 78 μm, V_m = 6.8 min^-1) that was hardly inhibited by orthovanadate. Using mutants of the conserved catalytic glutamate residues, the two NBDs of Vga(A) were shown to contribute unequally to the total ATPase activity, the mutation at NBD2 being more detrimental than the other. ATPase activity of both catalytic sites was essential for Vga(A) biological function because each single Glu mutant was unable to confer SgA resistance in the staphylococcal host. Of great interest, Vga(A) ATPase was specifically inhibited in a non-competitive manner by the SgA substrate, pristinamycin IIA (PIIA). A deletion of the last 18 amino acids of Vga(A) slightly affected the ATPase activity without modifying the PIIA inhibition values. In contrast, this deletion reduced 4-fold the levels of SgA resistance. Altogether, our results suggest a role for the C terminus in regulation of the SgA antibiotic resistance mechanism conferred by Vga(A) and demonstrate that this dual ATP-binding cassette protein interacts directly and specifically with PIIA, its cognate substrate.
Microbial export of lactic and 3-hydroxypropanoic acid: Implications for industrial fermentation processes
2004, Metabolic Engineering
Citation Excerpt :
The transport proteins involved often belong to the ATP-Binding-Cassette (ABC) transporter family (Higgins, 1992). ABC transporters have been found for the export of a wide variety of substrates, ranging from antibiotics to weak organic acids and proteins (Braibant et al., 2000; Higgins, 1992; Poelarends et al., 2000). For instance, in yeast, the ABC transporter PDR12 has been directly shown to lower the intracellular levels of benzoate by catalyzing an active efflux from the cell (Piper et al., 1998).
Lactic acid and 3-hydroxypropanoic acid are industrially relevant microbial products. This paper reviews the current knowledge on export of these compounds from microbial cells and presents a theoretical analysis of the bioenergetics of different export mechanisms. It is concluded that export can be a key constraint in industrial production, especially under the conditions of high product concentration and low extracellular pH that are optimal for recovery of the undissociated acids. Under these conditions, the metabolic energy requirement for product export may equal or exceed the metabolic energy yield from product formation. Consequently, prolonged product formation at low pH and at high product concentrations requires the involvement of alternative, ATP-yielding pathways to sustain growth and maintenance processes, thereby reducing the product yield on substrate. Research on export mechanisms and energetics should therefore be an integral part of the development of microbial production processes for these and other weak acids.
ABC-transporters: Implications on drug resistance from microorganisms to human cancers
2003, International Journal of Antimicrobial Agents
Resistance to chemotherapy is a common clinical problem in patients with infectious diseases as well as in patients with cancer. During treatment of infections or malignant tumors, the drug targets of prokaryotic or eukaryotic microorganisms and neoplastic cells are often found to be refractory to a variety of drugs that have different structures and functions. This phenomenon has been termed multidrug resistance (MDR). The mechanisms leading to MDR are frequently caused by trans-membrane xenobiotic transport molecules belonging to the superfamily of ATP-binding cassette (ABC) transporters. There is an urgent need to understand the structure-function relationships of these efflux pumps that underlie their transport mechanism and drug selectivity. This knowledge may allow the rational design of new drugs that can inhibit or circumvent the activity of these MDR transport molecules. Furthermore, the development of such chemosensitizing agents would help us learn more about the physiological functions and substrates of these pump proteins. This review will discuss the current state of knowledge of the functional and structural similarities among ABC-transporters in prokaryotic and eukaryotic cells and their impact on MDR.
The transmembrane domains of the ABC multidrug transporter LmrA form a cytoplasmic exposed, aqueous chamber within the membrane
2002, Journal of Biological Chemistry
The ABC multidrug transporter LmrA ofLactococcus lactis consists of six putative transmembrane segments (TMS) and a nucleotide binding domain. LmrA functions as a homodimer in which the two membrane domains form the solute translocation path across the membrane. To obtain structural information of LmrA a cysteine scanning accessibility approach was used. Cysteines were introduced in the cysteine-less wild-type LmrA in each hydrophilic loop and in TMS 6, and each membrane-embedded aromatic residue was mutated to cysteine. Of the 41 constructed single cysteine mutants, only one mutant, L301C, was not expressed. Most single-cysteine mutants were capable of drug transport and only three mutants, F37C, M299C, and N300C, were inactive, indicating that none of the aromatic residues in the transmembrane regions of LmrA are crucial for substrate binding or transport. Modification of the active mutants with N-ethylmaleimide blocked the transport activity in five mutants (S132C, L174C, S206C, S234C, and L292C). All cysteine residues in external and internal loops were accessible to fluorescein maleimide. The labeling experiments also showed that this thiol reagent cannot cross the membrane under the conditions used and confirmed the presence of six TMSs in each monomeric half of the transporter. Surprisingly, several single cysteines in the predicted TMSs could also be labeled by the bulky fluorescein maleimide molecule, suggesting unrestricted accessibility via an aqueous pathway. The periodicity of fluorescein maleimide accessibility of residues 291 to 308 in TMS 6 showed that this membrane-spanning α-helix has one face of the helix exposed to an aqueous cavity along its full-length. This finding, together with the solvent accessibility of 11 of 15 membrane-embedded aromatic residues, indicates that the transmembrane domains of the LmrA transporter form, under nonenergized conditions, an aqueous chamber within the membrane, which is open to the intracellular milieu.

View all citing articles on Scopus

View full text

Regular ArticleAn ABC-type multidrug transporter of Lactococcus lactis possesses an exceptionally broad substrate specificity

Abstract

J Biol Chem

J Biol Chem

Biochim Biophys Acta

J Biol Chem

Cell

Biochim Biophys Acta

J Biol Chem

Trends Biochem Sci

J Biol Chem

FEBS Lett

J Biol Chem

J Biol Chem

J Biol Chem

Prevention of drug access to bacterial targets: permeability barriers and active efflux

Science

How cancer cells evade chemotherapy

Cancer Res

Molecular properties of bacterial multidrug transporters

Microbiol Mol Biol Rev

Regular Article
An ABC-type multidrug transporter of Lactococcus lactis possesses an exceptionally broad substrate specificity